A Genetic Variant Ameliorates Β-Thalassemia Severity by Epigenetic-Mediated Elevation of Human Fetal Hemoglobin Expression

Diyu Chen,Yangjin Zuo,Xinhua Zhang,Yuhua Ye,Xiuqin Bao,Haiyan Huang,Wanicha Tepakhan,Lijuan Wang,Junyi Ju,Guangfu Chen,Mincui Zheng,Dun Liu,Shuodan Huang,Lu Zong,Changgang Li,Yajun Chen,Chenguang Zheng,Lihong Shi,Quan Zhao,Qiang Wu,Supan Fucharoen,Cunyou Zhao,Xiangmin Xu
DOI: https://doi.org/10.1016/j.ajhg.2017.05.012
2017-01-01
Abstract:A delayed fetal-to-adult hemoglobin (Hb) switch ameliorates the severity of beta-thalassemia and sickle cell disease. The molecular mechanism underlying the epigenetic dysregulation of the switch is unclear. To explore the potential cis-variants responsible for the Hb switching, we systematically analyzed an 80-kb region spanning the beta-globin cluster using capture-based next-generation sequencing of 1142 Chinese beta-thalassemia persons and identified 31 fetal hemoglobin (HbF)-associated haplotypes of the selected 28 tag regulatory single-nucleotide polymorphisms (rSNPs) in seven linkage disequilibrium (LD) blocks. A Ly1 antibody reactive (LYAR)-binding motif disruptive rSNP rs368698783 (G/A) from LD block 5 in the proximal promoter of hemoglobin subunit gamma 1 (HBG1) was found to be a significant predictor for beta-thalassemia clinical severity by epigenetic-mediated variant-dependent HbF elevation. We found this rSNP accounted for 41.6% of beta-hemoglobinopathy individuals as an ameliorating factor in a total of 2,738 individuals from southern China and Thailand. We uncovered that the minor allele of the rSNP triggers the attenuation of LYAR and two repressive epigenetic regulators DNA methyltransferase 3 alpha (DNMT3A) and protein arginine methyltransferase 5 (PRMT5) from the HBG promoters, mediating allele-biased gamma-globin elevation by facilitating demethylation of HBG core promoter CpG sites in erythroid progenitor cells from beta-thalassemia persons. The present study demonstrates that this common rSNP in the proximal A gamma-promoter is a major genetic modifier capable of ameliorating the severity of thalassemia major through the epigenetic-mediated regulation of the delayed fetal-to-adult Hb switch and provides potential targets for the treatment of beta-hemoglobinopathy.
What problem does this paper attempt to address?